Get started

Healthcare

RDHL | Good Entry Point | LONGRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
NASDAQ:RDHLLong
by DivergenceSeeker
2
KERN | Huge Institutional Ownership | LONGAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that offers tracking, reporting, and compliance tools to cannabis cultivators, processors, sellers, and clinics. Further, it provides cannabis cultivation management and compliance software; and cannabis tracking technology that offers seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.
KLong
by DivergenceSeeker
Two healthcare leaders, which one is best to own? NASDAQ:PODD & NASDAQ:DXCM are leading the sectors recovery. Both are in the Medical Products Industry for diabetes. Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms. For the recent correction, PODD has a -45% deep base while DXCM has a -58%. PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since. So, it really depends on your strategy. If you are looking for aplha then NASDAQ:DXCM is the stock for you but, if you prefer low beta then NASDAQ:PODD is better. Remember that aplha plays in both ways! Which are you trading? I'll trade the first that makes a new high.
NASDAQ:PODDLong
by dpuleo19
NKTX | Oversold Healthcare Play | LONGNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NASDAQ:NKTXLong
by DivergenceSeeker
SNDA | Great Entry Point | LONGSonida Senior Living, Inc. develops, owns, operates, and manages senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It also offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, such as meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry services, as well as special care services for residents with various forms of dementia. In addition, the company provides memory care services; and home care services through third-party providers. As of December 31, 2021, it operated 75 senior housing communities in 18 states with an aggregate capacity of approximately 9,500 residents, including 60 senior housing communities. The company was formerly known as Capital Senior Living Corporation and changed its name to Sonida Senior Living, Inc. in November 2021. Sonida Senior Living, Inc. was founded in 1990 and is based in Addison, Texas.
NYSE:SNDALong
by DivergenceSeeker
JOHNSON & JOHNSON Can reach $190 by FebruaryJohnson & Johnson (JNJ) has been trading within a long-term Bullish Megaphone pattern since the January 26 2021 High. The pattern has been having very structured Higher Highs and Higher Lows. At the moment the stock is on a bullish leg, after rebounding exactly on the 1D MA50 (blue trend-line) on November 11 and is also above the 1D MA200 (orange trend-line). The 1W MACD is on a Bullish Cross and the 1W RSI rebounded off a Lower Lows (Double) Bottom formation. The exact same sequence was last seem early this year on January. After one last pull-back, the stock then rallied to the top (Higher Highs trend-line) of the Bullish Megaphone. The Higher Highs seem to be following the 1.236 - 1.5 - 1.786 Fibonacci sequence and so do the Lows (0.236 - 0.5 - 0.786). The 1.786 Fib extension is a little over $190.00 and that is our current long target on JNJ. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
2
UnitedHealthGroup Analysis 19.11.2022Welcome to the BasicTrading channel. My name is Philip and in todays analysis I quickly go over the situation which we currently have on UnitedHealth Group. I will analyse the asset both from a weekly and daily timeframe to show you the best possible trading opportunities. If you enjoyed this analysis, let me know in the comment section which asset I should analyse tomorrow. I will personally reply to every single comment. Dont forget to smash that rocket and I will see you tomorrow with a new analysis.
NYSE:UNH
by basictradingtv
3
PHG | Strong Positive Volume | LONGKoninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
NYSE:PHGLong
by DivergenceSeeker
CLNN | Lets Get It | Extremely OversoldClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
NASDAQ:CLNNLong
by DivergenceSeeker
1
Specialized education that secures jobs equals +100% from lowsAdtalem Global Education is a leading healthcare educator that partners with organizations to address workforce needs and empower career development across the medical and healthcare industries. I've been watching this stock for a while and finally is signaling an actionable pivot buy. Price is close to its 50-day MA which can act as a good support level. I'd place mi stop just below it. Yesterday's volume was above average so I'll wait until near the close to assess today's volume. This stock is up +100% from its February low, that's right it bottomed in February. If this is not leadership, don't know what it is.
NYSE:ATGELong
by dpuleo19
RVP | RSI Curling Upward | LONGRetractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
AMEX:RVPLong
by DivergenceSeeker
Are you looking for stocks to buy? I am $PCTY $CCRNThe thing is, I'm buying very small positions. I use the averages like the SP:SPX and NASDAQ:IXIC more like a sentiment measure. The averages are that, averages. They don't account for the whole market. There will always be stocks rising or falling regardless of what the indexes are doing. But, if the averages are in downtrends I won't buy aggressively. I like these two stocks, NASDAQ:PCTY and NASDAQ:CCRN . They are both leaders in the outsorcing industry. Coincidence? Cross Country HealthCare provides market-leading workforce solutions and healthcare staffing services. And Paylocity provides software for payroll solution designed for the employee experience. I'll buy a close above Friday's high with a stop loss just below the Friday's low. Also I'll be watching volume very closely as in both momentum is still bullish.
NASDAQ:PCTYLong
by dpuleo19
$HUM, $XLV, Healthcare sector worth watching nowIf you have been invested in healthcare stocks or ETF's you may want to take profits between now and the end of October. I am keeping an eye on this chart for some good trades. It is a low volume stock with very low options volume, so be very selective with your entry time/place and your option price. Daily trading ranges can be large or small, so give extra consideration to time frame and holding time in your trade plan. Please note on the chart: * Linear regression channel shown from 2019 * Yellow dashed lines showing 370-470 trading range * Light yellow rectangle shows two-year range which was recently broken higher * White line (channel center) regularly acts as support or resistance, price is wavering along this line * RSI only had one instance of going over 67 (white oval) or under 33 since 2019, and that resulted in sharp reversal, for now it is moving lower * Stochastic %D has completed three peaks since dipping below 30 and is now turning down Price was weak on Monday and closed lower, but still in its recent range (sideway. I am looking at a few possibilities for trades: * If the market rallies this week HUM may stay under the white line and selloff down to 457, 435 * If the anticipated October leg down occurs, then price may move up to analysts' 550 price target (also top of channel) * Price has been sideways for two weeks, so it should move higher/lower soon
NYSE:HUM
by OptionsRising
4
8 Reasons Why Medtronic is a Great Investment OptionMedtronic is a medical device company that focuses on research, development, manufacturing, and distribution of various medical devices. The company has grown rapidly in the last few years thanks to its strong performance and focus on innovation. In this article, we will discuss why Medtronic remains a strong investment option with a promising future ahead. Reasons to invest in Medtronic The strong financial position of Medtronic is one of the main reasons to invest in it. The company’s debt-to-equity ratio is below 1.0, which means that its debt is well below its equity base. This is an important ratio to watch as an investor, especially if the company is heavy on debt – as that indicates that the company may run into trouble in the future especially in times like these where interest rates are going up. The company’s return on equity (ROE) is consistently above its cost of equity, which means that it is earning much more than its shareholders could expect in a risk-free investment. Similarly, Medtronic’s debt-to-asset ratio is below 40%, which shows that its debt is lower than its assets. This is important to look at when evaluating a company’s financial position, as it indicates the company is mostly likely to be able to pay back its debt even in a worst-case scenario. Strong Financial Position Another factor to consider when evaluating a company’s financial position is its liquidity. Liquidity is the ability of a company to quickly turn its assets into cash if needed. When it comes to Medtronic, the company has enough liquidity thanks to its cash on hand, cash from operations, and other short-term investments that can easily be turned into cash. Similarly, Medtronic’s current ratio (the number of current assets compared to current liabilities) is above 1.0, which indicates that the company has enough current assets to meet its current liabilities. This ratio is important to look at because it indicates whether or not a company can meet its short-term obligations while also pursuing long-term goals. Strong Track Record of Growth Through Acquisitions Medtronic has a strong track record of growth through acquisitions, having acquired dozens of companies in its history. This is important to watch out for when investing in a company – especially if it has a history of poor acquisitions. This can lead to lost capital for investors as well as a company that is unfocused. However, the acquisitions Medtronic has made have all been successful and focused around the company’s core business. This has allowed Medtronic to offer a wide range of products around the world while also keeping its R&D focused on the most important innovations. Integration of CareLink with Guardian 2 platform Another example of a successful acquisition is when Medtronic purchased CareLink in 2015 for $250 million. CareLink is a company focused on creating remote patient monitoring solutions that are designed to help patients manage chronic diseases at home. Following the acquisition, CareLink was integrated into Medtronic’s Guardian 2 remote care platform, which connects patients and doctors while also allowing patients to monitor their own health. This represents a huge opportunity for Medtronic as it expands its remote monitoring capabilities. This is especially relevant as more and more people are living with chronic conditions that require consistent monitoring. This is expected to lead to a huge opportunity for remote monitoring solutions in the future. Solid Return on Investment for Medtronic Investors When looking at the company’s return on investment (ROI), it is important to note that this is a long-term number. This means that you want to see a high ROI, but this number is not as important as a company’s short-term numbers. However, when it comes to investment, the long-term numbers are actually more important than the short-term numbers. The short-term numbers are important because they indicate how strong of a short-term investment a company is. The long-term numbers are important because they show the potential for long-term growth. Solid Base of Popular Brands/Products for Medtronic Another important factor to look at when evaluating Medtronic is its core products and brands. These are the products and brands that define Medtronic as a company, and they are what has helped the company grow over the last few decades. These products/brands can give us insight into Medtronic’s future plans, because the company has to consistently update and improve these products to meet consumer demand. Medtronic is venturing into the artificial intelligence space One of the biggest trends in the medical device industry is the adoption of artificial intelligence (AI). AI can be used to help medical devices better understand their environment and collect data/information on patients while also allowing them to communicate with other devices. This can be extremely helpful in the medical device industry, especially when it comes to remote monitoring solutions – which is an area in which Medtronic is already growing. One of Medtronic’s key acquisitions in recent years was HealthMine, which is a company focused on the AI space within medical devices. This acquisition could allow Medtronic to significantly expand its AI capabilities and help the company keep up with the latest trends in its industry. Financials EPS Dividend Yield % Valuation Metrics Summing up There are many reasons why Medtronic is a great investment option. The company has a strong financial position, a strong track record of growth through acquisitions, an integration of its CareLink acquisition with its Guardian 2 platform, a solid base of popular brands/products for Medtronic, and Medtronic is venturing into the artificial intelligence space. These are all reasons to invest in Medtronic because they show a strong future ahead.
NYSE:MDTLong
by EQTSHARES
31
AHPI | Under-valued PlayAllied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. The company was incorporated in 1979 and is headquartered in St. Louis, Missouri.
ALong
by DivergenceSeeker
HCAT Technical trade THIS IS NOT ADVICEThis ticker looks to be expanding its name with recent acquisitions, but the real reason for the trade is technical in nature, with clear momentum to the upside, horizontal resistance levels being turned to support, bullish divergence on the longer time frame, technicals are setup to look for a return to previous levels off the backs of a strong Bulldiv rally from oversold levels, setting a stop below the recent swing low allows for a technical trade plan that removes emotion. The slightly impressive R/R lines up with the bottom of the recent march low making it conservative, too. if the position is large enough, it could be managed through selling calls and use the premiums to hedge against a drop, just close out any short calls before dumping shares and make sure any short calls are initially sold with a strike above entry. AS ALWAYS!! make sure that any calls sold are done so with a full understanding of any possible dividend liabilities or obligations. NOT ADVICE, SIMPLY FOR FUN AND THEORY
NASDAQ:HCATLong
by rolledchange